TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03705273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone IV for PO
Description: Common pediatric emergency department practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone crushed tablets
Description: Alternative route of administration for patients unable to swallow tablet whole
Study: NCT03794882

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: 30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Medical Management
Description: Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Management
Description: Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
Study: NCT01218867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
Study: NCT04023422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical intervention
Description: The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical intervention
Description: The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical intervention
Description: The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback
Description: The community health navigator will give the clinician real-time feedback on guideline-related health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: The community health navigator will give the clinician real-time feedback on guideline-related health.
Study: NCT01218867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
Study: NCT04023422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: The community health navigator will give the clinician real-time feedback on guideline-related health.
Study: NCT03661918

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 10 Core Coaching Calls Only
Description: Participant will receive 10 core phone coaching sessions
Study: NCT01949272

Intervention type: DEVICE
Intervention: esophageal pressure mesurement
Description: EXPRESS study ventilatory setting the optimization of PEEP with esophageal pressure mesurement
Study: NCT00775034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisseel®
Description: Mesh repair for open incisional hernia repair with fibrin sealant

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Drainage
Description: Mesh repair for open incisional hernia repair with drainage
Study: NCT02082951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic behaviour by nurses.
Description: The empathic behaviour in group 1 was performed by a trained nurse.
Study: NCT01792362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss diet
Description: Control the patients diet to make them loosing weight
Study: NCT04415697

Intervention type: DIAGNOSTIC_TEST
Intervention: Gene expression test using nanostring technology.
Description: Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology

Intervention type: DIAGNOSTIC_TEST
Intervention: Gene expression test using nanostring technology.
Description: Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology
Study: NCT01556763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124 (0.3 mg/day)
Description: EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
Study: NCT02082951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic behaviour by family.
Description: Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
Study: NCT00494312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
Study: NCT04261166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1
Description: Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1
Description: Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1
Description: Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A2
Description: Medical Cannabis oil diluted in Olive oil. CBD 0.6 mg, THC 3.1 mg (1 drop)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3
Description: Medical Cannabis oil diluted in Olive oil. CBD 3.1 mg. THC 3.1 mg (1 drop)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4
Description: Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4
Description: Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4
Description: Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4
Description: Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A5
Description: Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A5
Description: Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1
Description: Sublingual tablets. CBD 40 mg, THC 2 mg (1 tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B2
Description: Sublingual tablets. CBD 30 mg, THC 5 mg (1 tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B3
Description: Sublingual tablets. CBD 40 mg (1 tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B4
Description: Sublingual tablets. CBD 40 mg (1 tablet)
Study: NCT01556763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124 (1.0 mg/day)
Description: EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
Study: NCT04261166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B4
Description: Sublingual tablets. CBD 40 mg (1 tablet)
Study: NCT04596423

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography
Description: fetal heart examination by medical ultrasound
Study: NCT01556763

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo was administered as one capsule per day for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic therapy
Description: Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
Study: NCT04596423

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography
Description: fetal heart examination by medical ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography
Description: fetal heart examination by medical ultrasound
Study: NCT01556763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic therapy
Description: Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antipsychotic therapy
Description: Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
Study: NCT03003546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel/Rituximab-coated Nanoparticle AR160
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03381508

Intervention type: DEVICE
Intervention: Brizzy continuous positive pressure device
Description: Patients are treated with the Brizzy continuous positive pressure device, including pneumotachograph.
Study: NCT02353832

Intervention type: DEVICE
Group type: OTHER
Intervention: Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)
Description: Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
Study: NCT02245100

Intervention type: OTHER
Intervention: Cytology specimen
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study: NCT06100380

Intervention type: OTHER
Intervention: Survey
Description: Questionnaire

Intervention type: OTHER
Intervention: Survey
Description: Questionnaire
Study: NCT02126787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Group Analytic Psychotherapy
Description: The form of intensive group analytic therapy to be used in the trial has been manualized by the research team for the study. It is rooted in group analysis tradition (Bion 1961; Foulkes \& Anthony, 1965). It is based on two recent group analytic psychotherapy manuals, one developed by Lorentzen (2014), the other by Garland (2010). The manual has been adapted to day treatment setting and also draws on polish psychoanalytical group experiences practiced in a public service. Like in other psychodynamic short-term therapies this approach is more structured and focused on issues relevant to symptoms relief. Thereby additional techniques are used: psychodrama, non-verbal techniques, movie therapy, memoir, summary or relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive transdiagnostic cognitive-behavioral group therapy
Description: GCBT was designed for treatment in naturalistic settings of diagnostically mixed anxiety disorder patients with comorbid Personality Disorders (PD's) (Holas, Szaniawska, Suszek, Błażejewski, \& Kokoszka, in prep.). It is based on the transdiagnostic approach to emotional and particularly anxiety disorders that has been developed over the past ten years (Barlow, 2000; Barlow, Allen, \& Choate, 2004; Norton, 2006), additionally it includes interventions for personality disorders based of schema therapy and modes of personality disorders. This approach assumes a high overlap between anxiety disorders and is focused on the common aspects of them. Intensive GCBT developed by our group shares the classical assumptions of cognitive-behavioral therapy (Beck, 1976).
Study: NCT05093751

Intervention type: OTHER
Intervention: Observation
Description: This study does not involve any intervention to subjects.
Study: NCT01706224

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Samples will be tested to determine the presence of anti-pertussis antibodies.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Samples will be tested to determine the presence of anti-pertussis antibodies.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Samples will be tested to determine the presence of anti-pertussis antibodies.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Samples will be tested to determine the presence of anti-pertussis antibodies.

Intervention type: OTHER
Intervention: Data collection
Description: Electronic Case Report Forms (eCRF)

Intervention type: OTHER
Intervention: Data collection
Description: Electronic Case Report Forms (eCRF)
Study: NCT04681378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double layer step up-step down technique
Description: the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double layer step up-step down technique
Description: the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double layer step up-step down technique
Description: the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
Study: NCT02090257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRANSIT
Description: Educational Modules, staff follow up.
Study: NCT01706224

Intervention type: OTHER
Intervention: Data collection
Description: Electronic Case Report Forms (eCRF)

Intervention type: OTHER
Intervention: Data collection
Description: Electronic Case Report Forms (eCRF)
Study: NCT01432327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenseWear display
Description: Participants use the self-monitoring device (display) to aid behavior change via real-time lifestyle feedback targeting physical activity.~The display has a versatile design that allows it to be clipped to a shirt, bag or belt loop. The Display can help participants stay in sync with their daily goals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Participants receive a pedometer to determine their daily amount of steps. Every day they write down their amount of steps in a step diary.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SenseWear Armband
Description: Participants wear the SenseWear Armband for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Coaching
Description: A weekly meeting with a Personal Coach to evaluate the physical activity patterns in daily life
Study: NCT01706224

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaires, active questioning.

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaires, active questioning.

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaires, active questioning.

Intervention type: OTHER
Intervention: Data collection
Description: Questionnaires, active questioning.
Study: NCT02556450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolacton
Description: Administration of Spironolacton 25 mg per day
Study: NCT01378520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 600 mg capsule oral once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inert powder
Description: oral once
Study: NCT04447820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER (Dose A)
Description: Dose A Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER (Dose B)
Description: Dose B Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-IR
Description: K-877-IR Oral Administration
Study: NCT01890577

Intervention type: DRUG
Intervention: Aranesp
Description: Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
Study: NCT03978390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral priming
Description: Priming the children with images of superheroes in order to behave desirably during the dental injection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral priming
Description: Priming the children with images of superheroes in order to behave desirably during the dental injection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: endowment effect
Description: Giving the rewards to children before starting the dental treatment and telling children they can only keep it if they behave desirably during the dental procedure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: endowment effect
Description: Giving the rewards to children before starting the dental treatment and telling children they can only keep it if they behave desirably during the dental procedure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive reinforcement
Description: Giving rewards to the children at the end if they cooperate desirably during the treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive reinforcement
Description: Giving rewards to the children at the end if they cooperate desirably during the treatment